These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30267958)

  • 1. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine.
    Li W; Li Y; Liu Z; Kerdsakundee N; Zhang M; Zhang F; Liu X; Bauleth-Ramos T; Lian W; Mäkilä E; Kemell M; Ding Y; Sarmento B; Wiwattanapatapee R; Salonen J; Zhang H; Hirvonen JT; Liu D; Deng X; Santos HA
    Biomaterials; 2018 Dec; 185():322-332. PubMed ID: 30267958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Nanoparticle Morphology on Enhancing Delivery of Budesonide for Treatment of Inflammatory Bowel Disease.
    Li Q; Liu W; Liu K; Dong Z; Kong W; Lu X; Wei Y; Wu W; Yang J; Qi J
    ACS Appl Mater Interfaces; 2024 Jul; 16(26):33081-33092. PubMed ID: 38888094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
    Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
    J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
    Ali H; Weigmann B; Collnot EM; Khan SA; Windbergs M; Lehr CM
    Pharm Res; 2016 May; 33(5):1085-92. PubMed ID: 26718953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy.
    Naeem M; Choi M; Cao J; Lee Y; Ikram M; Yoon S; Lee J; Moon HR; Kim MS; Jung Y; Yoo JW
    Drug Des Devel Ther; 2015; 9():3789-99. PubMed ID: 26229440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [DDS preparations of drugs for inflammatory bowel disease].
    Takada K
    Nihon Rinsho; 1999 Nov; 57(11):2508-15. PubMed ID: 10572421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease.
    Li S; Xie A; Li H; Zou X; Zhang Q
    J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redox-sensitive nanoparticles based on 4-aminothiophenol-carboxymethyl inulin conjugate for budesonide delivery in inflammatory bowel diseases.
    Sun Q; Luan L; Arif M; Li J; Dong QJ; Gao Y; Chi Z; Liu CG
    Carbohydr Polym; 2018 Jun; 189():352-359. PubMed ID: 29580419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycyrrhizic acid-loaded pH-sensitive poly-(lactic-co-glycolic acid) nanoparticles for the amelioration of inflammatory bowel disease.
    Zeeshan M; Ali H; Khan S; Mukhtar M; Khan MI; Arshad M
    Nanomedicine (Lond); 2019 Aug; 14(15):1945-1969. PubMed ID: 31355705
    [No Abstract]   [Full Text] [Related]  

  • 12. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.
    Date AA; Halpert G; Babu T; Ortiz J; Kanvinde P; Dimitrion P; Narayan J; Zierden H; Betageri K; Musmanno O; Wiegand H; Huang X; Gumber S; Hanes J; Ensign LM
    Biomaterials; 2018 Dec; 185():97-105. PubMed ID: 30236840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.
    Youshia J; Lamprecht A
    Expert Opin Drug Deliv; 2016; 13(2):281-94. PubMed ID: 26637060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease.
    Friend DR
    Aliment Pharmacol Ther; 1998 Jul; 12(7):591-603. PubMed ID: 9701522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Locally acting corticosteroids in inflammatory bowel disease. Are they effective? Are they really less toxic?].
    Nos Mateu P
    Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():16-21. PubMed ID: 19087859
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
    Gross V
    Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
    Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V
    Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oral drug delivery system with programmed drug release and imaging properties for orthotopic colon cancer therapy.
    Song Q; Jia J; Niu X; Zheng C; Zhao H; Sun L; Zhang H; Wang L; Zhang Z; Zhang Y
    Nanoscale; 2019 Aug; 11(34):15958-15970. PubMed ID: 31418432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa.
    Vafaei SY; Esmaeili M; Amini M; Atyabi F; Ostad SN; Dinarvand R
    Carbohydr Polym; 2016 Jun; 144():371-81. PubMed ID: 27083829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH-triggered surface charge-reversal nanoparticles alleviate experimental murine colitis via selective accumulation in inflamed colon regions.
    Naeem M; Oshi MA; Kim J; Lee J; Cao J; Nurhasni H; Im E; Jung Y; Yoo JW
    Nanomedicine; 2018 Apr; 14(3):823-834. PubMed ID: 29353017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.